1 Press folder Annual Conference Servier presents its Research and Development programmes Thursday 1 st December 2016 9 – 11 am 4 bis passage Landrieu, Paris 7 ème In the presence of: - Emmanuel CANET, Executive Vice-President of R&D - Eric FALCAND, Vice-President of Business Development and Licensing - Isabelle Tupinon-Mathieu, Director of Cardiovascular and Metabolism Innovation Divisions, Vice-President of R&D - Olivier Geneste, Director of Oncology Research - Hans-Martin Schneble, Director of Neurology Project
15
Embed
Servier presents its Research and Development programmes · Servier presents its Research and Development programmes Thursday 1st December 2016 9 ... Diamicron ® (gliclazide) was
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Press folder
Annual Conference
Servier presents its
Research and Development
programmes
Thursday 1st December 2016
9 – 11 am
4 bis passage Landrieu, Paris 7ème
In the presence of:
- Emmanuel CANET, Executive Vice-President of R&D
- Eric FALCAND, Vice-President of Business Development and Licensing
- Isabelle Tupinon-Mathieu, Director of Cardiovascular and Metabolism Innovation
Divisions, Vice-President of R&D
- Olivier Geneste, Director of Oncology Research
- Hans-Martin Schneble, Director of Neurology Project
2
I. Research and innovation: main axis of development for the group
A long tradition and recognised experience
The Servier group has always been strongly committed to research and development. The
Suresnes Research Centre opened in 1960, only six years after the creation of the initial
laboratory in Orléans.
In 1988, Servier was named the most creative laboratory worldwide by the Scrip magazine
and in 2002, the group received the Galien prize, which rewards its creative research.
The group's areas of excellence are cardiology and diabetes, but Servier has also always had
research teams in neurosciences, rheumatology and oncology, in order to meet the growing
medical needs in these areas.
Servier has always been committed to the therapeutic advances for the benefit of patients.
A) The strategic directions of the group in terms of Research and Development
As an average sized group (21,200 collaborators, turnover of 4 billion euros), choices must
be made on which diseases to specialise in so as to develop a very high level of expertise.
In 2015, Servier redefined its strategic directions in terms of research and development in
order to better use its expertise while meeting medical needs that have not been fulfilled.
Aim: to strengthen the group's leadership in cardiovascular diseases and diabetes,
and play a leading role in the fight against cancer, immunoinflammatory diseases and
neurodegenerative diseases.
Therefore, in cooperation with its R&D teams, Servier established academic collaborations
and partnerships to more effectively meet the needs of patients and to build a balanced risk-
taking portfolio of projects.
B) Building a portfolio, the outcome of long-term reflection
Today, to meet the requirements for specialisation, innovation and speed of marketing new
drugs, laboratories can no longer go it alone. Given the complexity and rapid evolution of
areas such as oncology or neurodegenerative diseases, it is no longer possible to master all
the recent knowledge and technologies alone. Working within a network is essential. For
two thirds of its drug candidates, Servier has partners but the emphasis is placed on
collaboration and joint participation in the different stages of development. The aim is to
best use the competencies of each partner and to benefit from their strengths for making
new drugs available to doctors and patients. These partnerships can therefore consist of
taking approved molecules or entrusting Servier molecules to other groups, as both actions
3
can be done with the same partner. It may also entail collaborations on scientific or
technological approaches.
However, the success of these partnerships is related to the competences of the internal
teams, recognised for their know-how and capable of identifying the most innovative
projects.
These approaches, for example, have allowed European patients to access the anti-cancer
drug Lonsurf in 2016.
C) Some key figures
23 drug candidates in clinical development, including 17 new molecular entities.
CARDIOVASCULAR
DISEASES
Heart failure
DIABETES
Type 2
diabetes
CANCERS
Solid tumours
and malignant
haemopathies
IMMUNOINFLAMMATORY
DISEASES
Autoimmune diseases
NEURODEGENERATIVE
DISEASES
Neurodegenerative
diseases
25% of Servier turnover invested in R&D
2,200 collaborators, 9th investor of the European Union in R&D in the pharmaceutical
sector
3 research centres, including 2 in France
One ambitious objective: to launch one new molecular entity every 3 years
4
II. A historical leader position in cardiovascular diseases and diabetes
1) Cardiovascular diseases
Hypertension and vascular disease
In the area of hypertension, Servier is the only pharmaceutical laboratory to have a fairly
extensive range, making it the 1st player in Europe and the 2nd worldwide.
A) General information
Hypertension is a major public health problem for a country like France. It is in fact the most
common of chronic illnesses with an estimated number of hypertensive patients between
14 and 16 million. The risk of hypertension increases with age: one in three French people
over the age of 35 years is hypertensive but after 65 years, it is one in two French people.
This condition is defined simply with blood pressure figures beyond a set threshold of
140/90 mmHg (14/9 when your doctor informs you of your pressure).
According to the World Health Organisation (WHO), hypertension is today the number one
cardiovascular risk factor worldwide. Out of 100 diagnosed hypertensive patients, it is
estimated that 20 are not treated and that 50 among those who are treated do not meet the
treatment objective. It is essential to inform a hypertensive patient of the dietary and
lifestyle measures, but in most cases, medical treatment will be necessary. This treatment
will need to be personalised by taking into account the patient’s specific characteristics.
B) Positioning of the Servier group and portfolio
Positioning
The product portfolio in the cardiovascular field offers prescribing physicians the most
extensive choice of treatment solutions, so as to offer each patient a treatment that is
adapted to their risk profile and their main comorbidities (diabetes or dyslipidaemia
particularly), and if necessary, fixed-dose combinations (up to 3 active ingredients) within a
same tablet to facilitate a patient's treatment compliance.
Existing Servier portfolio
9 products are currently on the market:
Coversyl: treatment for hypertension and heart failure
5
Cosyrel: for hypertensive patients suffering from coronary heart disease
Coveram: treatment for essential hypertension and/or stable coronary heart disease
Natrilix: diuretic
Natrixam: for elderly hypertensive patients
Preterax: for hypertensive patients with diabetes or following a stroke